Literature DB >> 9838898

Primary central nervous system tumors: advances in knowledge and treatment.

M D Prados1, M S Berger, C B Wilson.   

Abstract

The ability to diagnose, monitor, and treat CNS tumors has been improved by new imaging techniques such as positron emission tomography (PET) scanning and functional MR imaging, stereotactic surgery, delivery of radiotherapy with brachytherapy and radiosurgery, and novel methods for delivering chemotherapy. These innovations combined with the new information about tumor pathogenesis and behavior revealed by molecular research give hope that more specific treatments for malignant CNS tumors will be developed in the future.

Entities:  

Mesh：

Year:  1998        PMID： 9838898     DOI： 10.3322/canjclin.48.6.331

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


  12 in total

1.  Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours.

Authors:  Michelangelo Bartolo; Chiara Zucchella; Andrea Pace; Gaetano Lanzetta; Carmine Vecchione; Marcello Bartolo; Giovanni Grillea; Mariano Serrao; Cristina Tassorelli; Giorgio Sandrini; Francesco Pierelli
Journal:  J Neurooncol       Date:  2011-11-29       Impact factor: 4.130

Review 2.  Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases.

Authors:  Decha Pinkaew; Ken Fujise
Journal:  Adv Clin Chem       Date:  2017-08-07       Impact factor: 5.394

Review 3.  Immunologic approaches to therapy for brain tumors.

Authors:  D B Paul; C A Kruse
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

4.  The influence of preoperative dependency on mortality, functional recovery and complications after microsurgical resection of intracranial tumors.

Authors:  Martin N Stienen; David Y Zhang; Morgan Broggi; Dominik Seggewiss; Stefano Villa; Silvia Schiavolin; Oliver Bozinov; Niklaus Krayenbühl; Johannes Sarnthein; Paolo Ferroli; Luca Regli
Journal:  J Neurooncol       Date:  2018-05-02       Impact factor: 4.130

5.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

6.  Glioma cell integrin expression and their interactions with integrin antagonists: Research Article.

Authors:  Ralph-Heiko Mattern; Susana B Read; Michael D Pierschbacher; Chun-I Sze; Brian P Eliceiri; Carol A Kruse
Journal:  Cancer Ther       Date:  2005

7.  Reduced glioma infiltration in Src-deficient mice.

Authors:  Caren V Lund; Mai T N Nguyen; Geoffrey C Owens; Andrew J Pakchoian; Ashkaun Shaterian; Carol A Kruse; Brian P Eliceiri
Journal:  J Neurooncol       Date:  2006-03-22       Impact factor: 4.130

8.  Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.

Authors:  German G Gomez; Marileila Varella-Garcia; Carol A Kruse
Journal:  Cancer Genet Cytogenet       Date:  2006-03

9.  Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

Authors:  German G Gomez; Carol A Kruse
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

10.  Elevated cell invasion in a tumor sphere culture of RSV-M mouse glioma cells.

Authors:  Motonobu Nonaka; Toshio Yawata; Mitsuhiro Takemura; Youichirou Higashi; Eiichi Nakai; Keiji Shimizu; Tetsuya Ueba
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-12-20       Impact factor: 1.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.